CRCbioscreen is a spinoff from the Netherlands Cancer Institute. CRCbioscreen is dedicated to developing a unique next generation stool test that is cost-effective and well-suited for population-based colorectal cancer screening. CEO is Henri Theunissen, a seasoned entrepreneur and innovation expert who has extensive expertise in building and growing Life Sciences startups. CSO Professor Gerrit Meijer and COO Dr. Meike de Wit have longstanding experience in the field of colorectal cancer detection and biomarker development. The team has published over one hundred papers related to colorectal cancer screening.